In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity: Implications in cancer chemotherapy

European Journal of Cancer

Volumn 39, Issue 17, 2003, Pages 2556-2565

  Das, B ^a   Yeger, H ^a   Baruchel, H ^a   Freedman, M H ^a   Koren, G ^a   Baruchel, S ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Apoptosis; Cisplatin toxicity; Cytoprotection; Glutathione; Neuroblastoma; Squalene

Indexed keywords

ANTIOXIDANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; ISOPRENOID; SQUALENE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASUREMENT; MONOLAYER CULTURE; NEUROBLASTOMA; NICK END LABELING; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0242299690     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.07.002     Document Type: Article

References (39)

1. Bukowski R. The need for cytoprotection. Eur J Cancer. 32A:1999;S2-S4.
2. Hensley M.L., Schuchter L.M., Lindley C.et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17:1999;3333-3355.
3. Shaw P.J., Bleakley M. Systemic inflammatory response syndrome associated with amifostine. Med. Pediatr. Oncol. 34:2000;309-310.
4. Jahnukainen K., Jahnukainen T., Salmi T.T., Svechnikov K., Eksborg S., Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res. 61:2001;6423-6427.
5. Fouladi M., Stempak D., Gammon J.et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 92:2001;914-923.
6. Zhang K., Chew M., Yang E.B., Wong K.P., Mack P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol. Pharmacol. 59:2001;837-843.
7. Hospers G.A., Eisenhauer E.A., de Vries E.G. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br. J. Cancer. 80:1999;629-638.
8. Baruchel S., Wang T., Farah R., Jamali M., Batist G. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. Biochem. Pharmacol. 50:1995;1505-1508.
9. Kleinman W.A., Richie J.P. Jr. Status of glutathione and other thiols and disulfides in human plasma. Biochem. Pharmacol. 60:2000;19-29.
10. Kohno Y., Egawa Y., Itoh S., Nagaoka S., Takahashi M., Mukai K. Kinetic study of quenching reaction of singlet oxygen and scavenging reaction of free radical by squalene in n-butanol. Biochim. Biophys. Acta. 1256:1995;52-56.
11. Storm H.M., Oh S.Y., Kimler B.F., Norton S. Radioprotection of mice by dietary squalene. Lipids. 28:1993;555-559.
12. Fan S., Ho I., Yeoh F.L., Lin C., Lee T. Squalene inhibits sodium arsenite-induced sister chromatid exchanges and micronuclei in Chinese hamster ovary-K1 cells. Mutat Res. 368:1996;165-169.
13. Kamimura H., Koga N., Oguri K., Yoshimura H. Enhanced elimination of theophylline, phenobarbital and strychnine from the bodies of rats and mice by squalane treatment. J. Pharmacobiodyn. 15:1992;215-221.
14. Richter E., Schafer S.G. Effect of squalane on hexachlorobenzene (HCB) concentrations in tissues of mice. J. Environ. Sci. Health B. 17:1982;195-203.
15. Rao C.V., Newmark H.L., Reddy B.S. Chemopreventive effect of squalene on colon cancer. Carcinogenesis. 19:1998;287-290.
16. Smith T.J., Yang G.Y., Seril D.N., Liao J., Kim S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis by dietary olive oil and squalene. Carcinogenesis. 19:1998;703-706.
17. Hamilton J.A., Byrene R., Whitty G. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. Leukocyte Biol. 67:2000;226-232.
18. Ikekawa T., Umeji M., Manabe T.et al. Study of antitumor activity of squalene and its related compounds. J Pharmacol Soc Jpn. 1990;106578-106582.
19. Ellis W.M., Georgiou G.M., Roberton D.M., Johnson G.R. The use of discontinuous Percoll gradients to separate populations of cells from human bone marrow and peripheral blood. J. Immunol. Methods. 66:1984;9-16.
20. Dimitroulakos J., Squire J., Pawlin G., Yeger H. NUB-7. a stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages Cell Growth Differ. 5:1994;373-384.
21. Sekiguchi M., Oota T., Sakakibara K., Inui N., Fujii G. Establishment and characterization of a human nueroblastoma cell line in tissue culture. Japan J. Exp. Med. 49:1979;67-83.
22. Cohn S.L., Salwen H., Quasney M.W.et al. High levels of N-myc protein in a neuroblastoma cell line lacking N-myc amplification. Progr. Clin. Biol. Res. 366:1991;21-27.
23. Sutherland H., Eaves A., Eaves C. Quantitative Assays for Human Hemopoietic Progenitor Cells. 1991;CRC Press, Boca Raton.
24. Eaves C., Lambi K. Atlas of Human Hematopoietic Colonies. 1995;Stem Cell Technologies Inc, Vancouver.
25. Sgonc R., Boeck G., Dietrich H., Gruber J., Recheis H., Wick G. Simultaneous determination of cell surface antigens and apoptosis. Trends Genet. 10:1994;41-42.
26. Fields R., Lancaster M. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am. Biotechnol. Lab. 11:1993;48-50.
27. Swartz M.A., Kristensen C.A., Melder R.J.et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br. J. Cancer. 81:1999;756-759.
28. McEvoy G.K. Antineoplastic Agents: Cisplatin. Drug Information. 1999, American Society of Health-System Pharmacists, Bethesda. 817.
29. Brodeur G.M., Maris J.M. Neuroblastoma. Pizzo P.A., Poplack D.G. Principle and Practice of Pediatric Oncology 4th edn. 2002;918 Lippincott Williams & Wilkins, Philadelphia.
30. List A.F., Heaton R., Glinsmann-Gibson B., Capizzi R.L. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 12:1998;1596-1602.
31. De Kimpe S., Anggard E., Carrier M. Reactive oxygen species regulate macrophage scavenger receptor type I, but not type II, in the human monocyte cell line THP-1. Mol. Pharmacol. 53:1998;1076-1082.
32. Links M., Lewis C. Chemoprotectants. a review of their clinical pharmacology and therapeutic efficacy Drugs. 57:1999;293-308.
33. Lee K., Kim K., Jung Y.et al. Induction of apoptosis in p53-deficient human hepatoma cells in wild-type p53 gene transduction. inhibition by antioxidant Mol. Cells. 12:2001;17-24.
34. Park S., Choi K., Bang J., Huh K., Kim S. Cisplatin-induced apoptotic cell death in a mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J. Neurochem. 75:2000;946-953.
35. Budavari M. The Merck Index. New Jersey, Merck, 1989, 8730.
36. Strandberg T.E., Tilvis R.S., Miettinen T.A. Metabolic variables of cholesterol during squalene feeding in humans. comparison with cholestyramine treatment J. Lipid Res. 31:1990;1637-1643.
37. Relas H., Gylling H., Miettinen T.A. Fate of intravenously administered squalene and plant sterols in human subjects. J. Lipid Res. 42:2001;988-994.
38. Liu G., Ahrens E.J., Schreibman P., Crouse J. Measurement of squalene in human tissues and plasma. validation and application J. Lipid Res. 17:1976;38-45.
39. Chan P., Tomlinson B., Lee C.B., Lee Y.S. Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. J. Clin. Pharmacol. 36:1996;422-427.